- Company
- Will the new social distancing benefit the prescription mkt?
- by Chon, Seung-Hyun Jun 25, 2021 05:51am
- New social distancing rules will be applied from next month. The restrictions set on private gatherings will be eased, and the operating hours of multi-use facilities will also be extended. The pharmaceutical industry has its eyes on whether the outpatient prescription market, which has contracted due to a decrease in outdoor activities, will ta
- Company
- Telemisartan is excluded from impurity survey
- by Kim, Jin-Gu Jun 25, 2021 05:51am
- The MFDS has expanded the scope of the impurity investigation to ARB drugs as a whole. However, Telmisartan·Azilsartan·Eprosartan were excluded from the list of additional investigations. The pharmaceutical industry understands that Telmisartan was excluded from the impurity survey because it does not have a tetrazole ring. The MFDS s
- Company
- Sillajen acquirer GFB seeks further partnership opportunity
- by Jun 24, 2021 05:55am
- "Using ShillaJen’s anticancer virus platform, we can add many new substances to be developed as novel drugs. Korea owns many excellent early-stage novel drug candidates, and we also may additionally introduce promising new substances in Korea." At the interview with DailyPharm, Ajit Gill, CEO of Greenfire Bio, Ajit Gill expressed his strong
- Company
- Benlysta can be reimbursed in general hospitals
- by Eo, Yun-Ho Jun 24, 2021 05:55am
- Benlysta, which has been covered by insurance benefits for the first time in seven years, can be reimbursed in general hospitals. According to related industries, GSK's Benlysta (Belimumab) has passed the drug committee (DC) of 20 hospitals nationwide, including Aju University Hospital, Chungnam National University Hospital and Hanyang Univer
- Company
- PARP inhibitors for primary ovarian cancer can be reimbursed
- by Jun 23, 2021 05:54am
- PARP inhibitors "Jejula" and "Lynparza" are expected to be applied to primary maintenance therapy for ovarian cancer as early as the third quarter. This is limited to BRCA mutations, and most patients without mutations do not benefit. According to the pharmaceutical industry on the 21st, Takeda followed by Lynparza (Olaparib) of AstraZenec
- Company
- Pfizer Korea suspends distribution of Champix
- by Kim, Jin-Gu Jun 23, 2021 05:54am
- Domestic supply of ‘Champix (varenicline),’ a smoking cessation product, has been suspended altogether. Pfizer Korea, which is in charge of supplying the product, explained that this was a preemptive measure made regarding the impurity issue. According to industry sources on the 23rd, Pfizer Korea had sent an official notice to domes
- Company
- Patients implore for 1st line reimbursement of Tagrisso
- by Jun 23, 2021 05:54am
- After a series of failures in receiving reimbursement extension for the EGFR targeted therapy ‘Tagrisso’ in the first-line setting of lung cancer, the patients have taken the reimbursement issue into their own hands and implored the government to review its reimbursement again. On the 22nd, the 1,713 lung cancer patients and their famil
- Company
- Pneumococcal vaccination rate drops due to COVID vaccination
- by Whang, byung-woo Jun 23, 2021 05:54am
- Compared to rate of inoculation in 2020, rate of inoculation decreased significantly in first quarter of 2021. As COVID vaccinations begin in earnest, the inoculation rate of pneumococcal vaccines, which rose sharply last year, is decreasing. In particular, it is difficult for health centers to be in charge of vaccination and the situation of
- Company
- Zolgensma applies for reimbursement... ignites discussion
- by Eo, Yun-Ho Jun 22, 2021 05:50am
- Another ultra-high priced ‘one-shot’ treatment has begun it process to be listed for reimbursement. Novartis, the developer of another one-shot treatment ‘Kyrmriah,' has announced its plans to list and release ‘Zolgensma’ in Korea. According to industry sources, Novartis has recently submitted an application for the reimbursement of
- Company
- PD-1 inhibitors enhance future value of anticancer treatment
- by Jun 22, 2021 05:50am
- Since its first appearance in 2011, cancer immunotherapies have opened a new paradigm in the field of cancer treatment. Moving on from the era of targeted therapies that target specific gene mutation, the new era had opened where a patient’s immune system is activated to remove the malignant tumor. The immunotherapies that have been comme
